BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31876540)

  • 21. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
    Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
    Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
    Kaplan HG; Malmgren JA; Atwood MK
    BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
    Applebaum MA; Vaksman Z; Lee SM; Hungate EA; Henderson TO; London WB; Pinto N; Volchenboum SL; Park JR; Naranjo A; Hero B; Pearson AD; Stranger BE; Cohn SL; Diskin SJ
    Eur J Cancer; 2017 Feb; 72():177-185. PubMed ID: 28033528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphologic and molecular analysis of early-onset gastric cancer.
    Setia N; Wang CX; Lager A; Maron S; Shroff S; Arndt N; Peterson B; Kupfer SS; Ma C; Misdraji J; Catenacci D; Hart J
    Cancer; 2021 Jan; 127(1):103-114. PubMed ID: 33048355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
    Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
    Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
    Patel JP; Gönen M; Figueroa ME; Fernandez H; Sun Z; Racevskis J; Van Vlierberghe P; Dolgalev I; Thomas S; Aminova O; Huberman K; Cheng J; Viale A; Socci ND; Heguy A; Cherry A; Vance G; Higgins RR; Ketterling RP; Gallagher RE; Litzow M; van den Brink MR; Lazarus HM; Rowe JM; Luger S; Ferrando A; Paietta E; Tallman MS; Melnick A; Abdel-Wahab O; Levine RL
    N Engl J Med; 2012 Mar; 366(12):1079-89. PubMed ID: 22417203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population.
    Lin KM; Shashidharan M; Ternent CA; Thorson AG; Blatchford GJ; Christensen MA; Lanspa SJ; Lemon SJ; Watson P; Lynch HT
    Dis Colon Rectum; 1998 Apr; 41(4):428-33. PubMed ID: 9559626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
    Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
    Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG
    JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial CEBPA-mutated acute myeloid leukemia.
    Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
    Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001.
    Ahmed F; Goodman MT; Kosary C; Ruiz B; Wu XC; Chen VW; Correa CN
    Cancer; 2006 Sep; 107(5 Suppl):1162-71. PubMed ID: 16838312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
    Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
    Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
    Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.
    Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'Brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM;
    Bone Marrow Transplant; 2014 May; 49(5):691-8. PubMed ID: 24535126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.